, Cancer today [Internet]. international agency for research on cancer, 2018.

D. Sur,

P. C. Valery, M. Laversanne, P. J. Clark, J. L. Petrick, K. A. Mcglynn et al., Projections of primary liver cancer to 2030 in 30 countries worldwide, Hepatology, vol.67, issue.2, pp.600-611, 2018.

F. Binder-foucard, N. Bossard, P. Delafosse, A. Belot, A. Woronoff et al., Cancer incidence and mortality in France over the 1980-2012 period: solid tumors, Rev Epidemiol Sante Publique. avr, vol.62, issue.2, pp.95-108, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01915012

N. Ganne-carrié,

. Afef--société-française-d'hépatologie, , 2019.

L. Defossez-gautier, . Guyader-peyrou-sandra, G. Uhry-zoe, C. Pascale, D. Marc et al., Estimations nationales de l'incidence et de la mortalité par cancer en France métropolitaine entre, Tumeurs solides : Étude à partir des registres des cancers du réseau Francim, vol.1, 1990.

D. Sur,

N. Goutté, P. Sogni, N. Bendersky, J. C. Barbare, B. Falissard et al., Geographical variations in incidence, management and survival of hepatocellular carcinoma in a Western country, J Hepatol, vol.66, issue.3, pp.537-581, 2017.

T. Akinyemiju, S. Abera, M. Ahmed, N. Alam, M. A. Alemayohu et al., The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level, JAMA Oncol. déc, vol.3, issue.12, pp.1683-91, 2017.

J. D. Yang, P. Hainaut, G. J. Gores, A. Amadou, A. Plymoth et al., A global view of hepatocellular carcinoma: trends, risk, prevention and management, Nat Rev Gastroenterol Hepatol, vol.16, issue.10, pp.589-604, 2019.

I. Rosa, J. Denis, R. P. Lesgourgues, B. Dobrin, A. S. Becker et al., 585 A FRENCH MULTICENTRIC LONGITUDINAL DESCRIPTIVE STUDY OF HEPATOCELLULAR CARCINOMA MANAGEMENT (THE CHANGH COHORT): PRELIMINARY RESULTS, Journal of Hepatology. 1 avr, vol.52, pp.231-233, 2010.

, Meeting of the Strategic Advisory Group of Experts on immunization, Weekly epidemiological record. déc, vol.48, issue.1, pp.729-776, 2017.

P. Nahon, R. Layese, V. Bourcier, C. Cagnot, P. Marcellin et al., Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs, Gastroenterology, vol.155, issue.5, pp.1436-1450, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02648450

P. R. Galle, A. Forner, J. M. Llovet, V. Mazzaferro, F. Piscaglia et al., Clinical Practice Guidelines: Management of hepatocellular carcinoma, Journal of Hepatology. juill, vol.69, issue.1, pp.182-236, 2018.

C. E. Costentin, R. Layese, V. Bourcier, C. Cagnot, P. Marcellin et al., Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study, Gastroenterology, vol.155, issue.2, pp.431-442, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02648451

, Critères diagnostiques et bilan initial de la cirrhose non compliquée (Actualisation de décembre, HAS synthèse des recommandations professionnelles, 2008.

J. F. Blanc, J. C. Barbare, A. S. Baumann, V. Boige, K. Boudjema et al.,

. «-carcinome-hépatocellulaire, Thésaurus National de Cancérologie Digestive, 2019.

L. Zhou, J. Rui, W. Zhou, S. Wang, S. Chen et al., Edmondson-Steiner grade: A crucial predictor of recurrence and survival in hepatocellular carcinoma without microvascular invasio. Pathology -Research and Practice, vol.213, pp.824-854, 2017.

G. Yu, S. Kim, S. Park, X. Cui, D. Xu et al., Identification of molecular markers for the oncogenic differentiation of hepatocellular carcinoma, Exp Mol Med, vol.39, issue.5, pp.641-52, 2007.

J. Calderaro, G. Couchy, S. Imbeaud, G. Amaddeo, E. Letouzé et al., Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification, J Hepatol, vol.67, issue.4, pp.727-765, 2017.

V. Violi, N. Lewis, S. Hectors, S. Said, D. Taouli et al., Radiological Diagnosis and Characterization of HCC, Hoshida Y, éditeur. Hepatocellular Carcinoma: Translational Precision Medicine Approaches

. Cham, , 2019.

C. E. Costentin, A. Mourad, P. Lahmek, X. Causse, A. Pariente et al., Hepatocellular carcinoma is diagnosed at a later stage in alcoholic patients: Results of a prospective, nationwide study. Cancer, vol.124, pp.1964-72, 2018.

P. J. Johnson, S. Berhane, C. Kagebayashi, S. Satomura, M. Teng et al., Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach-The ALBI Grade, J Clin Oncol. 20 févr, vol.33, issue.6, pp.550-558, 2015.

T. A. Labeur, S. Berhane, E. J. Blanc, J. Bettinger, D. Meyer et al., Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib, Liver International, vol.40, issue.1, pp.215-243, 2020.

C. Duvoux, F. Roudot-thoraval, T. Decaens, F. Pessione, H. Badran et al., Liver transplantation for hepatocellular carcinoma: a model including ?-fetoprotein improves the performance of Milan criteria, Gastroenterology, vol.143, issue.4, pp.986-994, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00865368

T. Arizumi, K. Ueshima, T. Minami, M. Kono, H. Chishina et al., Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma, Liver Cancer. déc, vol.4, issue.4, pp.253-62, 2015.

H. Nishikawa, R. Kita, T. Kimura, Y. Ohara, A. Sakamoto et al., Clinical implication of performance status in patients with hepatocellular carcinoma complicating with cirrhosis, J Cancer, vol.6, issue.4, pp.394-402, 2015.

C. Hsu, Y. Lee, C. Hsia, Y. Huang, C. Su et al., Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system, Hepatology. janv, vol.57, issue.1, pp.112-121, 2013.

A. Forner, M. Reig, J. Bruix, and . Hepatocellular, Lancet, vol.31, pp.1301-1315, 2018.

C. E. Costentin, C. R. Ferrone, R. S. Arellano, S. Ganguli, T. S. Hong et al., Hepatocellular Carcinoma with Macrovascular Invasion: Defining the Optimal Treatment Strategy, Liver Cancer, vol.6, issue.4, pp.360-74, 2017.

F. Huitzil-melendez, M. Capanu, E. M. O'reilly, A. Duffy, B. Gansukh et al., Advanced hepatocellular carcinoma: which staging systems best predict prognosis?, J Clin Oncol. 10 juin, vol.28, issue.17, pp.2889-95, 2010.

E. G. Giannini, L. Bucci, F. Garuti, M. Brunacci, B. Lenzi et al., Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice, Hepatology, vol.67, issue.5, pp.1784-96, 2018.

J. Barbare, D. Franco, T. André, J. Bronowicki, M. P. Péron et al., Should cases of hepatocellular carcinoma be discussed by non-specialized multidisciplinary team meetings?, Bull Cancer. juin, vol.101, issue.6, pp.558-63, 2014.
URL : https://hal.archives-ouvertes.fr/hal-02181349

F. Cauchy, S. Zalinski, S. Dokmak, D. Fuks, O. Farges et al., Surgical treatment of hepatocellular carcinoma associated with the metabolic syndrome, Br J Surg. janv, vol.100, issue.1, pp.113-134, 2013.

D. Cherqui, A. Laurent, N. Mocellin, C. Tayar, A. Luciani et al., Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation, Ann Surg, vol.250, issue.5, pp.738-784, 2009.

G. Germani, M. Pleguezuelo, K. Gurusamy, T. Meyer, G. Isgrò et al., Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis, J Hepatol. mars, vol.52, issue.3, pp.380-388, 2010.

A. Cucchetti, F. Piscaglia, M. Cescon, A. Colecchia, G. Ercolani et al., Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma, J Hepatol. août, vol.59, issue.2, pp.300-307, 2013.

C. Duvoux, Transplantation et carcinome hépatocellulaire

. Fmc-hge, , 2016.

D. Sur,

M. Feng, K. Suresh, M. J. Schipper, L. Bazzi, E. Ben-josef et al., Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial, JAMA Oncol. 1 janv, vol.4, issue.1, pp.40-47, 2018.

P. Merle, F. Mornex, and C. Trepo, Innovative therapy for hepatocellular carcinoma: three-dimensional high-dose photon radiotherapy, Cancer Lett. 1 déc, vol.286, issue.1, pp.129-162, 2009.

H. Bai, P. Gao, H. Gao, G. Sun, C. Dong et al., Improvement of Survival Rate for Patients with Hepatocellular Carcinoma Using Transarterial Chemoembolization in Combination with Three-Dimensional Conformal Radiation Therapy: A Meta-Analysis, Med Sci Monit. 26 mai, vol.22, pp.1773-81, 2016.

M. Boulin, E. Delhom, M. Pierredon-foulongne, J. Cercueil, and B. Guiu, Chimioembolisation des carcinomes hépatocellulaires : une vieille méthode au goût du jour, Journal de Radiologie Diagnostique et Interventionnelle. juin, vol.96, issue.2, pp.162-71, 2015.

R. Golfieri, E. Giampalma, M. Renzulli, R. Cioni, I. Bargellini et al., Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma, Br J Cancer. 15 juill, vol.111, issue.2, pp.255-64, 2014.

J. M. Llovet, C. Brú, and J. Bruix, Prognosis of hepatocellular carcinoma: the BCLC staging classification, Semin Liver Dis, vol.19, issue.3, pp.329-367, 1999.

. Lo-chung-mau, Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma, Disponible sur, vol.35, 2002.

J. M. Llovet, M. I. Real, X. Montaña, R. Planas, S. Coll et al., Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial, The Lancet, vol.359, issue.9319, pp.1734-1739, 2002.

F. Trevisani, Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Meta-Analysis of Randomized Controlled Trials, Disponible sur, vol.224, 2002.

J. Llovet, Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival, Hepatology, vol.37, issue.2, pp.429-442, 2003.

R. Lencioni, . Baere-t-de, M. C. Soulen, W. S. Rilling, and J. Geschwind, Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data, Hepatology, vol.64, issue.1, pp.106-122, 2016.

R. Lencioni, Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy, Crit Rev Oncol Hematol. août, vol.83, issue.2, pp.216-240, 2012.

G. H. Choi, J. H. Shim, M. Kim, M. Ryu, B. Ryoo et al., Sorafenib Alone versus Sorafenib Combined with Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: Results of Propensity Score Analyses, Radiology, vol.269, issue.2, pp.603-611, 2013.

R. Lencioni, J. M. Llovet, G. Han, W. Y. Tak, J. Yang et al., Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial, Journal of Hepatology, vol.64, issue.5, pp.1090-1098, 2016.

L. Liu, H. Chen, M. Wang, Y. Zhao, G. Cai et al., Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis, PLoS ONE, vol.9, issue.3, p.91124, 2014.

M. Kudo, K. Imanaka, N. Chida, K. Nakachi, W. Tak et al., Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma, European Journal of Cancer, vol.47, issue.14, pp.2117-2127, 2011.

F. Hucke, W. Sieghart, M. Pinter, I. Graziadei, W. Vogel et al., The ART-strategy: Sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma retreated with TACE, Journal of Hepatology. 1 janv, vol.60, issue.1, pp.118-144, 2014.

, Etude et de Traitement du Carcinome Hépatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma, N Engl J Med, vol.11, pp.1256-61, 1995.

R. Salem, R. J. Lewandowski, L. Kulik, E. Wang, A. Riaz et al., Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma, Gastroenterology. févr, vol.140, issue.2, pp.497-507, 2011.

R. Salem, A. C. Gordon, S. Mouli, R. Hickey, J. Kallini et al., Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma, Gastroenterology, vol.151, issue.6, pp.1155-1163, 2016.

J. Ricke, B. Sangro, H. Amthauer, I. Bargellini, P. Bartenstein et al., The impact of combining Selective Internal Radiation Therapy (SIRT) with sorafenib on overall survival in patients with advanced hepatocellular carcinoma: The SORAMIC trial palliative cohort, Annals of Oncology, vol.29, p.v110, 2018.

V. Vilgrain, H. Pereira, E. Assenat, B. Guiu, A. D. Ilonca et al., Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial, Lancet Oncol, vol.18, issue.12, pp.1624-1660, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01727346

P. Chow, M. Gandhi, S. Tan, M. W. Khin, A. Khasbazar et al., Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma, J Clin Oncol, vol.36, issue.19, pp.1913-1934, 2018.

J. Edeline, L. Crouzet, B. Campillo-gimenez, Y. Rolland, M. Pracht et al., Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis, Eur J Nucl Med Mol Imaging. avr, vol.43, issue.4, pp.635-678, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01217979

J. M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane et al., Sorafenib in advanced hepatocellular carcinoma, N Engl J Med. 24 juill, vol.359, issue.4, pp.378-90, 2008.
URL : https://hal.archives-ouvertes.fr/hal-02927464

A. Cheng, Y. Kang, Z. Chen, C. Tsao, S. Qin et al., Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial, The Lancet Oncology, vol.10, issue.1, pp.25-34, 2009.

S. Faivre, A. De-gramont, and R. E. , Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?, Target Oncol, vol.11, issue.4, pp.565-572, 2016.

V. Boige, J. Barbare, and O. Rosmorduc, Utilisation du sorafénib (Nexavar ® ) dans le traitement du carcinome hépatocellulaire : recommandations Prodige Afef, 2008.

D. Sur,

J. Blanc, F. Khemissa, J. Bronowicki, C. Monterymard, J. Perarnau et al., Results of the Phase II randomized French trial PRODIGE 21 comparing sorafenib vs pravastatin vs sorafenib and pravastatin vs best supportive care for the palliative treatment of HCC in CHILD B cirrhotic patients, Journal of Hepatology, vol.68, p.S195, 2018.

J. A. Marrero, M. Kudo, A. P. Venook, S. Ye, J. Bronowicki et al., Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study, Journal of Hepatology. déc, vol.65, issue.6, pp.1140-1147, 2016.

M. Kudo, R. S. Finn, S. Qin, K. Han, K. Ikeda et al., Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 noninferiority trial, Lancet, vol.24, pp.1163-73, 2018.

H. Autorité-de-santé,

D. Sur, Violence sexuelle et conséquences sur la santé, PrimaryCare, vol.13, issue.17, pp.308-309, 2013.

R. S. Finn, M. Ducreux, S. Qin, P. R. Galle, A. X. Zhu et al., IMbrave150: A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma., Journal of Clinical Oncology, vol.36, issue.15_suppl, pp.TPS4141-TPS4141, 2018.

R. S. Finn, S. Qin, M. Ikeda, P. R. Galle, M. Ducreux et al., Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma, New England Journal of Medicine, vol.382, issue.20, pp.1894-1905, 2020.

J. Bruix, S. Qin, P. Merle, A. P. Granito, Y. Huang et al., Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial, The Lancet, vol.389, issue.10064, pp.56-66, 2017.

S. Faure, Un nouvel inhibiteur de tyrosine kinase, Actualités Pharmaceutiques, vol.47, issue.473, p.8, 2008.

H. Autorité-de-santé, Évaluation des systèmes implantables de neurostimulation médullaire par la Haute Autorité de santé (HAS) en France, Chirurgie de la douleur, pp.143-148, 2014.

F. Karagonlar, Z. Koc, D. Iscan, E. Erdal, E. Atabey et al., Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells, Cancer Sci. avr, vol.107, issue.4, pp.407-423, 2016.

G. K. Abou-alfa, T. Meyer, A. Cheng, A. B. El-khoueiry, L. Rimassa et al., Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma, New England Journal of Medicine, vol.379, issue.1, pp.54-63, 2018.

J. Blanc, Traitement du Carcinome Hépatocellulaire avancé

. Fmc-hge, , 2019.

A. X. Zhu, Y. Kang, C. Yen, R. S. Finn, P. R. Galle et al., Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased ?-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial, The Lancet Oncology, vol.20, issue.2, pp.282-296, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02927464

. Bristol-myers, Squibb Announces Results from CheckMate -459 Study Evaluating Opdivo (nivolumab) as a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma | BMS Newsroom

A. X. Zhu, R. S. Finn, S. J. Cattan, J. Edeline, S. Ogasawara et al., KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib., Journal of Clinical Oncology, vol.36, issue.4_suppl, pp.209-209, 2018.

R. S. Finn, B. Ryoo, P. Merle, M. P. Kudo, M. Bouattour et al., Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial, Journal of Clinical Oncology, vol.38, issue.3, pp.193-202, 2020.

F. Bi, S. Qin, S. Gu, Y. Bai, Z. Chen et al., Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial., Journal of Clinical Oncology, vol.38, issue.15_suppl, pp.4506-4506, 2020.

Q. S. Li, S. Qin, S. Gu, X. Chen, L. Lin et al., Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study., Journal of Clinical Oncology, vol.38, issue.15_suppl, pp.4507-4507, 2020.

J. Raoul, B. Sangro, A. Forner, V. Mazzaferro, F. Piscaglia et al., Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization, Cancer Treatment Reviews, vol.37, issue.3, pp.212-220, 2011.
URL : https://hal.archives-ouvertes.fr/hal-01134844

J. Park, M. Chen, M. Colombo, L. R. Roberts, M. Schwartz et al., Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study, Liver International, vol.35, issue.9, pp.2155-2166, 2015.

J. K. Heimbach, L. M. Kulik, R. S. Finn, C. B. Sirlin, M. M. Abecassis et al., AASLD guidelines for the treatment of hepatocellular carcinoma, Hepatology, vol.67, issue.1, pp.358-380, 2017.

T. Xue, X. Xie, L. Zhang, X. Yin, B. Zhang et al., Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis, BMC Gastroenterology, vol.13, issue.1, p.60, 2013.

J. P. Silva, N. G. Berger, S. Tsai, K. K. Christians, C. N. Clarke et al., Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis, HPB, vol.19, issue.8, pp.659-666, 2017.

S. M. Chung, C. J. Yoon, S. S. Lee, S. Hong, J. W. Chung et al., Treatment Outcomes of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma that Invades Hepatic Vein or Inferior Vena Cava, CardioVascular and Interventional Radiology, vol.37, issue.6, pp.1507-1515, 2014.

C. S. Georgiades, K. Hong, M. D'angelo, and J. Geschwind, Safety and Efficacy of Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma and Portal Vein Thrombosis, Journal of Vascular and Interventional Radiology, vol.16, issue.12, pp.1653-1659, 2005.

G. E. Chung, J. Lee, H. Y. Kim, S. Y. Hwang, J. S. Kim et al., Transarterial Chemoembolization Can Be Safely Performed in Patients with Hepatocellular Carcinoma Invading the Main Portal Vein and May Improve the Overall Survival, Radiology, vol.258, issue.2, pp.627-634, 2011.

J. M. Llovet, J. Bustamante, A. Castells, R. Vilana, M. D. Ayuso et al., Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials, Hepatology, vol.29, issue.1, pp.62-67, 1999.

K. Uka, H. Aikata, S. Takaki, H. Shirakawa, S. Jeong et al., Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma, World Journal of Gastroenterology, vol.13, issue.3, p.414, 2007.

T. Okusaka, S. Okada, H. Ishii, H. Nose, H. Nagahama et al., Prognosis of hepatocellular carcinoma patients with extrahepatic metastases, Hepatogastroenterology. févr, vol.44, issue.13, pp.251-258, 1997.

D. Yoo, K. M. Kim, Y. Jin, J. H. Shim, G. Ko et al., Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: Does transarterial chemoembolization improve survival in these patients?, Journal of Gastroenterology and Hepatology, vol.26, issue.1, pp.145-154, 2010.

M. M. Kirstein, T. Voigtländer, N. Schweitzer, J. B. Hinrichs, J. Marquardt et al., Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease, United European Gastroenterology Journal, vol.6, issue.2, pp.238-246, 2017.

M. Pinter, F. Hucke, I. Graziadei, W. Vogel, A. Maieron et al., Advanced-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization versus Sorafenib, Radiology, vol.263, issue.2, pp.590-599, 2012.

S. M. Jung, J. W. Jang, C. R. You, S. H. Yoo, J. H. Kwon et al., Role of intrahepatic tumor control in the prognosis of patients with hepatocellular carcinoma and extrahepatic metastases, Journal of Gastroenterology and Hepatology, vol.27, issue.4, pp.684-689, 2012.

H. Nishikawa, Y. Osaki, E. Iguchi, H. Takeda, J. Nakajima et al., Comparison of the efficacy of transcatheter arterial chemoembolization and sorafenib for advanced hepatocellular carcinoma, Experimental and Therapeutic Medicine, vol.4, issue.3, pp.381-386, 2012.

J. Raoul, T. Decaens, K. Burak, J. Koskinas, G. E. Villadsen et al., Practice patterns and deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): Final analysis of OPTIMIS in Europe and Canada, Annals of Oncology, vol.29, p.viii240, 2018.

M. M. Kirstein, N. Schweitzer, N. Ay, C. Boeck, K. Lappas et al., Experience from a real-life cohort: outcome of 606 patients with hepatocellular carcinoma following transarterial chemoembolization, Scandinavian Journal of Gastroenterology, vol.52, issue.1, pp.116-124, 2016.

D. H. Sinn, J. Cho, G. Gwak, Y. Paik, M. S. Choi et al., Different Survival of Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma Patients by the Extent of Portal Vein Invasion and the Type of Extrahepatic Spread, PLOS ONE, vol.10, issue.4, p.e0124434, 2015.

. R-core-team, R: The R Project for Statistical Computing, 2015.

D. Sur, Eau disponible pour l'utilisation, 2017.

J. Bruix, J. Raoul, M. Sherman, V. Mazzaferro, L. Bolondi et al., Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial, Journal of Hepatology, vol.57, issue.4, pp.821-829, 2012.

Y. Zhao, R. Duran, J. Chapiro, J. H. Sohn, S. Sahu et al., Transarterial Chemoembolization for the Treatment of Advanced-Stage Hepatocellular Carcinoma, Journal of Gastrointestinal Surgery, vol.20, issue.12, pp.2002-2009, 2016.

K. Uchino, R. Tateishi, S. Shiina, M. Kanda, R. Masuzaki et al., Hepatocellular carcinoma with extrahepatic metastasis, Cancer, vol.117, issue.19, pp.4475-4483, 2011.

G. Cabibbo, M. Enea, M. Attanasio, J. Bruix, A. Craxì et al., A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma, Hepatology, vol.51, issue.4, pp.1274-1283, 2009.

J. Bruix, A. Cheng, G. Meinhardt, K. Nakajima, Y. De-sanctis et al., Corrigendum to ?Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies? [J hepatol 67 (2017) 999?1008], Journal of Hepatology, vol.69, issue.4, pp.990-991, 2018.

R. A. Miksad, S. Ogasawara, F. Xia, M. Fellous, and F. Piscaglia, Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study, BMC Cancer, vol.19, issue.1, p.795, 2019.

A. Fohlen, J. P. Tasu, H. Kobeiter, J. M. Bartoli, J. P. Pelage et al., Transarterial chemoembolization (TACE) in the management of hepatocellular carcinoma: Results of a French national survey on current practices, Diagnostic and Interventional Imaging, vol.99, issue.9, pp.527-535, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02006533

F. Lachenal, Aspects éthiques de la prise de décision de transfert (ou non-transfert) en réanimation des patients porteurs d?hémopathies malignes, Éthique & Santé, vol.8, issue.3, pp.160-165, 2011.

I. Krakowski, AFSOS: Association francophone pour les soins oncologiques de support « Améliorer le développement et l?excellence des soins de supports? Améliorer la vie des équipes », Oncomagazine, vol.3, issue.3, pp.10-11, 2009.

D. Sur,

. Serment-d'hippocrate, Au moment d'être admise à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité. Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux

. Prâevost, Â. M. Chomprâe, A. Deleyre, J. Green, A. Meusnier-de-querlon et al., Histoire gâenâerale des voyages, ou, Nouvelle collection de toutes les relations de voyages par mer et par terre, qui ont âetâe publiâees jusqu'áa present dans les diffâerentes langues de toutes les nations connues : contenant ce qu'il y a de plus remarquable, de plus utile et de mieux averâe dans les pays ou les voyageurs ont penetrâe : touchant leur situation, leur âetendue, leurs limites, leurs divisions, leur climat, leur terroir, leurs productions, leurs lacs, leurs rivieres, leurs montagnes, leurs mines, leurs citâes & leurs principales villes, leurs ports, leurs rades, leurs edifices, &c. : avec les moeurs et les usages des habitans, leur religion, leur gouvernement, leurs arts et leurs sciences, leur commerce et leurs manufactures : pour former un systâeme complet d'histoire et de gâeographie moderne, qui representera l'âetat actuel de toutes les nations : enrichi de cartes gâeographiques nouvellement composâees sur les observations les plus autentiques :, 1746.

. Prâevost, Â. M. Chomprâe, A. Deleyre, J. Green, A. Meusnier-de-querlon et al., Histoire gâenâerale des voyages, ou, Nouvelle collection de toutes les relations de voyages par mer et par terre, qui ont âetâe publiâees jusqu'áa present dans les diffâerentes langues de toutes les nations connues : contenant ce qu'il y a de plus remarquable, de plus utile et de mieux averâe dans les pays ou les voyageurs ont penetrâe : touchant leur situation, leur âetendue, leurs limites, leurs divisions, leur climat, leur terroir, leurs productions, leurs lacs, leurs rivieres, leurs montagnes, leurs mines, leurs citâes & leurs principales villes, leurs ports, leurs rades, leurs edifices, &c. : avec les moeurs et les usages des habitans, leur religion, leur gouvernement, leurs arts et leurs sciences, leur commerce et leurs manufactures : pour former un systâeme complet d'histoire et de gâeographie moderne, qui representera l'âetat actuel de toutes les nations : enrichi de cartes gâeographiques nouvellement composâees sur les observations les plus autentiques :, 1746.

, Comment puis-je me tenir informé des technologies les plus récentes, des nouveaux modèles de fabrication, et de la recherche-développement?, 2003.

L. Madsen-brooks, « Je ne me suis pas perdue et ne souhaite pas que l?on me trouve ». Stratégies des femmes dans les musées de sciences en Californie (xixe-, Culture & musées, issue.30, pp.111-131, 2017.

M. Sandras, « Je ne suis pas un écrivain, je suis le poète qui chante » Les entretiens de Paul Fort avec Michel Manoll, Écrivains au micro, pp.201-15

W. Coolsaet, "Je speelt, je wint. Je verliest. Je speelt" Reflecties bij Jeanette Winterson, De passie, De Uil van Minerva, vol.21, issue.2-3, 2006.

M. Demélas-bohy, «Je suis oiseau ; voyez mes ailes...», «Je suis souris : vive les rats !», Caravelle, vol.62, issue.1, pp.179-191, 1994.